Dr. Elan S. Diamond, MD

Dr. Diamond practices at Summit Medical Group - Berkley Heights Campus in Saddle Brook, New Jersey.

Dr. Diamond's NPI, 1659530608, was assigned on June 5, 2008. Dr. Diamond graduated from Weill Cornell Medicine in 2008. Dr. Diamond's New Jersey license number on file is 25MA09722600.

Dr. Diamond's primary practice is Summit Medical Group - Berkley Heights Campus, at 160 Pehle Ave, Saddle Brook, NJ 07663 in Bergen County. The practice phone is (908) 273-4300.

Dr. Diamond's primary practice is Summit Medical Group - Berkley Heights Campus in Saddle Brook, New Jersey. Dr. Diamond is also affiliated with Hackensack University Medical Center. The medical group on file is Summit Health. Dmand AI also links Dr. Diamond to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Diamond practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Diamond's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Diamond is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Diamond's licenses on file in 2 states: New Jersey and New York.

Dmand AI lists colorectal cancer, lung cancer and prostate cancer among the conditions Dr. Diamond treats.

CMS data shows 78,770 Medicare services from Dr. Diamond across 41 procedure codes in 2024, for 540 Medicare patients. Medicare paid $2,585,412 for them. Every service was in an office.

CMS counts 540 Medicare patients who saw Dr. Diamond in 2024. The largest group is 65 to 74, with 227 patients. 75% of them have cancer, and 75% have high blood pressure. 3% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Diamond's median patient age at 75, with 10% women.

In 2024, Dr. Diamond wrote 4,020 Medicare Part D claims for 425 patients. 65% of them were for generic drugs. CMS names the drug for 3,789 of them, across 31 drugs with 11 or more claims each, at $15,627,390 in total drug cost. In 2023, CMS named 3,448 claims across 29 drugs.

Dr. Diamond accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Diamond as offering telehealth.

Dmand AI links 8 papers to Dr. Diamond, published from 2012 to 2025. 2012 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols and Prostatic Neoplasms. Dr. Diamond's most frequent co-authors are David M. Nanus, MD, Scott T. Tagawa, MD and Laurence H. Belkoff, DO.

Dmand AI links Dr. Diamond to 10 clinical trials, 4 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Lobular and Cholangiocarcinoma. Alliance for Clinical Trials in Oncology sponsors the most, 4.

CMS Open Payments shows 119 general payments to Dr. Diamond from 29 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $30,111.

Dr. Diamond graduated from Weill Cornell Medicine in 2008.

Dr. Diamond is in network with 18 carriers, including Blue Cross Blue Shield of Michigan, Horizon Blue Cross Blue Shield of New Jersey and United Healthcare. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.